JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $67
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $65 to $67.
JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $65 to $67.